- Home
- MEOH vs ACAD Comparison
MEOH vs ACAD Comparison
Compare MEOH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEOH
- ACAD
- Stock Information
- Founded
- MEOH 1968
- ACAD 1993
- Country
- MEOH Canada
- ACAD United States
- Employees
- MEOH N/A
- ACAD N/A
- Industry
- MEOH Major Chemicals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- MEOH Industrials
- ACAD Health Care
- Exchange
- MEOH Nasdaq
- ACAD Nasdaq
- Market Cap
- MEOH 1.8B
- ACAD 2.5B
- IPO Year
- MEOH N/A
- ACAD 2004
- Fundamental
- Price
- MEOH $32.32
- ACAD $16.93
- Analyst Decision
- MEOH Buy
- ACAD Buy
- Analyst Count
- MEOH 8
- ACAD 15
- Target Price
- MEOH $47.25
- ACAD $24.21
- AVG Volume (30 Days)
- MEOH 721.8K
- ACAD 1.7M
- Earning Date
- MEOH 04-30-2025
- ACAD 05-07-2025
- Dividend Yield
- MEOH 2.34%
- ACAD N/A
- EPS Growth
- MEOH 24.27
- ACAD N/A
- EPS
- MEOH 3.06
- ACAD 1.37
- Revenue
- MEOH $3,700,592,000.00
- ACAD $996,283,000.00
- Revenue This Year
- MEOH $13.55
- ACAD $13.07
- Revenue Next Year
- MEOH $7.13
- ACAD $10.06
- P/E Ratio
- MEOH $10.61
- ACAD $12.55
- Revenue Growth
- MEOH 2.77
- ACAD 22.42
- 52 Week Low
- MEOH $25.46
- ACAD $13.40
- 52 Week High
- MEOH $56.43
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- MEOH 52.31
- ACAD 64.73
- Support Level
- MEOH $31.65
- ACAD $14.45
- Resistance Level
- MEOH $33.45
- ACAD $15.31
- Average True Range (ATR)
- MEOH 1.19
- ACAD 0.66
- MACD
- MEOH 0.67
- ACAD 0.27
- Stochastic Oscillator
- MEOH 83.81
- ACAD 90.91
About MEOH Methanex Corporation
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through a global supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.